低分子肝素钙与重组人尿激酶原对肺栓塞症疗效  

Efficacy of Low Molecular Weight Heparin Calcium and Recombinant Human Prourokinase on Pulmonary Embolism

作　　者：尚俊依[1] 王金来 刘姿[1] 杨正波[2] Shang Junyi;Wang Jin;Liu Zi;Yang Zhengbo(Department of Respiratory and Critical Care Medicine,Henan Provincial People's Hospital,Zhengzhou 450003;Department of Anesthesiology and Perioperative Medicine,Henan Provincial People's Hospital,Zhengzhou 450003)

机构地区：[1]河南省人民医院呼吸与危重症医学科,郑州450003 [2]河南省人民医院麻醉与围术期医学科,郑州450003

出　　处：《数理医药学杂志》2021年第6期892-894,共3页Journal of Mathematical Medicine

摘　　要：目的:探究低分子肝素钙与重组人尿激酶原对肺栓塞症的临床疗效。方法:选取2018年1月~2020年1月期间某院呼吸内科与心血管科收治的100例肺栓塞患者,根据治疗方案分为对照组和观察组各50例,对照组仅予以低分子肝素钙抗凝治疗,观察组予以低分子肝素钙联合重组人尿激酶原联合治疗,观察对比两组临床疗效。结果:观察组患者治疗后的SBP、PaO_(2)指标水平均显著高于对照组,其PASP指标水平显著低于对照组(P<0.05);观察组患者治疗后的TM、PC、D-D、t-PA、PAI-1指标水平均显著低于对照组(P<0.05);观察组的不良反应总发生率(6.00%)显著低于对照组(20.00%)(P<0.05)。结论:低分子肝素钙与重组人尿激酶原在肺栓塞临床治疗中的联用效果更佳,更具安全性,值得推广。Objective:To explore the clinical effects of low molecular weight heparin calcium and recombinant human prourokinase on pulmonary embolism.Methods:A total of 100 patients with pulmonary embolism admitted to a hospital from January 1,2018 to January 1,2020 were selected and divided into control group and observation group according to the treatment plan.Fifty patients in the control group were given low-molecular-weight heparin calcium anticoagulation therapy,and 50 patients in the observation group were given low-molecular-weight heparin calcium combined with recombinant human prourokinase.The clinical efficacy of the two groups was compared.Results:The SBP and PaO_(2) index levels of the observation group after treatment were significantly higher than those of the control group,and their PASP index levels were significantly lower than those of the control group(P<0.05).The TM,PC,D-D,t-PA,and PAI-1 index level of observation group was significantly lower than those of the control group(P<0.05).The total incidence of adverse reactions in the observation group(6.00%)was significantly lower than that of the control group(20.00%,P<0.05).Conclusion:The combination of low-molecular-weight heparin calcium and recombinant human prourokinase in the clinical treatment of pulmonary embolism is more effective,safer,and worthy of promotion.

关 键 词：肺栓塞症 低分子肝素钙 重组人尿激酶原 不良反应 安全性 

分 类 号：R563.5[医药卫生—呼吸系统]